|Bid||14.50 x 200|
|Ask||14.98 x 5000|
|Day's Range||14.56 - 14.94|
|52 Week Range||6.41 - 17.40|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The number of biotech stocks posting gains outstripped those recording losses for the week. Notable among the gainers for the week were Odonate Therapeutics Inc (NASDAQ: ODT ) — which reported its financial ...
Athenex and Amicus Therapeutics are a few noticeable companies with a strong future outlook. The market’s optimistic sentiment towards these stocks indicates a level of confidence in the future outlookRead More...
From acquisitions and equipment purchases to stock buybacks, firms are rapidly recalibrating their business plans in the wake of the corporate-tax overhaul. Specialty drugmaker Amicus Therapeutics, for ...
Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Amicus Therapeutics, Inc. Here are 5 ETFs with the largest exposure to FOLD-US. Comparing the performance and risk of Amicus Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Individual investors like stocks with a high growth potential. These companies have a strong outlook that can bring a significant upside to your portfolio, regardless of market cyclicality. Analysing theRead More...
Amicus Therapeutics Inc (NASDAQ:FOLD), a biotechnology company based in United States, saw a decent share price growth in the teens level on the NasdaqGM over the last few months. WithRead More...
On a per-share basis, the Cranbury, New Jersey-based company said it had a loss of 69 cents. Losses, adjusted for one-time gains and costs, came to 41 cents per share. The results missed Wall Street expectations. ...
Amicus Therapeutics, Inc. (FOLD) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Amicus Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
Sarepta Therapeutics and Amicus Therapeutics are tackling the unmet need for new treatments for rare conditions, and that could put them in position to generate market-beating returns.
Biotech stocks narrowed in on a 21-month high Wednesday with big rises coming from the likes of Intercept, Amicus and Exelixis on positive drug and partnership news.